A5064669297- Liver Disease Diagnosis and Treatment
- Hepatitis B Virus Studies
- Hepatitis C virus research
- Liver Disease and Transplantation
- Liver Diseases and Immunity
- Hepatocellular Carcinoma Treatment and Prognosis
- Alcohol Consumption and Health Effects
- Pancreatitis Pathology and Treatment
- Drug Transport and Resistance Mechanisms
- Pancreatic and Hepatic Oncology Research
- Hepatitis Viruses Studies and Epidemiology
- Metabolism, Diabetes, and Cancer
- Diabetes Management and Research
- Drug-Induced Hepatotoxicity and Protection
- Hormonal and reproductive studies
- Artificial Intelligence in Healthcare
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Pleural and Pulmonary Diseases
- Organ Transplantation Techniques and Outcomes
- Medical Imaging and Pathology Studies
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Lipoproteins and Cardiovascular Health
- Colorectal Cancer Screening and Detection
- Diet, Metabolism, and Disease
- HIV/AIDS drug development and treatment
Chinese University of Hong Kong
2018-2025
Prince of Wales Hospital
2019-2021
Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) can inhibit liver fibrogenesis in animal models. We aimed to evaluate the impact of ACEI/ARB use on risk cancer cirrhosis complications patients with NAFLD.We conducted a retrospective, territory-wide cohort study adult NAFLD diagnosed between January 2000 December 2014 allow for at least 5 years follow-up. ACEI or ARB users were defined as who had received treatment 6 months. The primary endpoint was...
Patients with chronic hepatitis B (CHB) are aging because of improved survival under better health care. This has an important implication on the choice antiviral treatment (AVT), given that long‐term safety would be a concern in presence multiple comorbidities. We aimed to determine prevalence key comorbidities and concomitant medications territory‐wide CHB cohort Hong Kong 2000‐2017. patients who have been care at primary, secondary, tertiary medical centers public sector were identified...
We compared risk of acute liver injury and mortality in patients with COVID-19 current, past, no HBV infection.This was a territory-wide retrospective cohort study Hong Kong. Patients between January 23, 2020, 1, 2021, were identified. hepatitis C or HBsAg results excluded. The primary outcome mortality. Acute defined as alanine aminotransferase aspartate ≥2 × upper limit normal (ULN; i.e., 80 U/L), total bilirubin ULN (i.e., 2.2 mg/dL) and/or international normalized ratio ≥1.7. Of 5,639...
INTRODUCTION: Immunotherapy has dramatically improved the survival of patients with advanced or metastatic malignancies. Recent studies suggest that immunotherapy may increase risk hepatitis, whereas it also induce functional cure chronic hepatitis B virus (HBV) infection. We evaluated incidence flare, HBV reactivation, surface antigen (HBsAg) seroclearance seroreversion in current past infection who had received immunotherapy. METHODS: This was a territory-wide observational cohort study...
Summary Background Universal vaccination of newborns with hepatitis B virus (HBV) vaccine is the most important strategy to prevent chronic HBV infection and its complications which hepatocellular carcinoma (HCC) as deadliest. Aims To evaluate impact universal on prevalence infection, incidences HCC hepatic events in young adults born before after introduction programme 1988 Hong Kong Methods This was a territory‐wide retrospective observational cohort study consecutive adult subjects...
Background and Aims: It is unclear if the leading causes of death in patients with NAFLD differ by age. We aimed to investigate relative importance liver‐related deaths lower overshadowed cardiovascular cancer‐related elderly population. Approach Results: conducted a territory‐wide retrospective cohort study adult between 2000 2021 Hong Kong. The outcomes interest were all‐cause cause‐specific mortality. Age groups at studied 10‐year intervals. During 662,471 person‐years follow‐up 30,943...
We aimed to test the hypothesis that automated fibrosis score calculation and electronic reminder messages could increase detection of advanced liver disease in patients with type 2 diabetes.
Abstract Background & Aims FibroScan® Expert 630 and Mini+430 are novel vibration‐controlled transient elastography devices equipped with the same SmartExam software, which allows continuous measurement of controlled attenuation parameter (CAP) during entire examination. This study aims to compare CAP variabilities quantification for liver fibrosis steatosis between conventional FibroScan SmartExam‐equipped machines in patients metabolic dysfunction‐associated steatotic disease (MASLD)....
We previously demonstrated the possible noninferiority of a screening strategy for varices guided by liver and spleen stiffness measurement (LSSM) compared to universal endoscopic in detecting clinically significant patients with cirrhosis. now report long-term outcome recruited this trial incident variceal bleeding other hepatic events. This was prospective follow-up study noninferiority, open-label, randomized controlled (NCT02024347) 548 adult known chronic diseases, radiological evidence...
Abstract Background and Aim Male sex is a risk factor for hepatocellular carcinoma (HCC). Diabetes mellitus (DM) associated with doubled of HCC in patients chronic hepatitis B (CHB). We examined the relationship between serum total testosterone male CHB DM. Methods performed retrospective cohort study DM 2000 2017 using territory‐wide electronic health‐care database Hong Kong. was defined by use anti‐diabetic medications, hemoglobin A 1c ≥ 6.5%, and/or fasting glucose 7 mmol/L two...
Antiviral treatment is known to improve survival in patients with chronic hepatitis B (CHB)-related hepatocellular carcinoma (HCC). Yet, the uptake CHB remains low. We aimed report secular trend antiviral from 2007-2017, and compare effect of different nucleos(t)ide analogue (NA) initiation times (before vs. after HCC diagnosis) on survival. A 3-month landmark analysis was used overall not receiving NA (i.e. no NA), NAs their first post-HCC ≤3 months before pre-HCC NA). propensity...
Summary Background Baveno VII was proposed for non‐invasive identification of clinically significant portal hypertension. However, a substantial proportion patients is classified in the grey zone ( i.e ., liver stiffness 15–24.9 kPa and/or platelet count <150 × 10 9 /L). Aims To evaluate risk and predictors hepatic decompensation zone, to determine prognostic role spleen measurement. Methods We included prospective cohorts (from Hong Kong, Korea France) who had undergone transient...
It is unknown whether patients with chronic hepatitis B (CHB) who achieved surface antigen (HBsAg) seroclearance spontaneously or following anti-viral therapy have similar clinical outcomes.To compare the risk of hepatocellular carcinoma (HCC) in CHB either cleared HBsAg METHODS: Adult CHB-monoinfected between January 2000 and March 2019 were identified from a territory-wide database Hong Kong. Patients liver transplantation and/or HCC before loss excluded. Patients' demographics,...
Abstract Background & Aims The steatosis‐associated fibrosis estimator (SAFE) score was developed to detect clinically significant liver in patients with NAFLD the United States. We compare performance of SAFE and other non‐invasive tests diagnose correlate scores liver‐related outcomes Hong Kong. Methods This a retrospective cohort study involving two data sets. first biopsy ( n = 279), second territory‐wide 4603) retrieved from electronic healthcare database Results In detecting...
Summary Background The Liver stiffness measurement hepatocellular carcinoma (LSM‐HCC) score predicts HCC accurately in patients with chronic hepatitis B (CHB). Aim To assess the ability of LSM‐HCC combined enhanced liver fibrosis (ELF) to predict CHB who received anti‐viral treatment. Methods had transient elastography examinations 2006‐2013 intermediate and high risk by (ie 11 or above) were assessed repeat at least 3 years later. ELF was retrieving stored serum samples 4 weeks within...
Abstract Thiazolidinediones (TZDs) improve glycaemic control and ameliorate liver steatosis, inflammation fibrosis in patients with fatty disease. We aimed to study the impact of TZD on risk hepatocellular carcinoma (HCC) hepatic events diabetic chronic hepatitis B (CHB). performed a retrospective cohort CHB 2000‐2017 using territory‐wide electronic healthcare database Hong Kong. Diabetes mellitus was identified by use any antidiabetic medication, haemoglobin A 1c (HbA ) ≥6.5%, fasting...